Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07391657 · ClinicalTrials.gov registry record · Phase 3

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

A Phase 3 study of Relapsed Refractory Multiple Myeloma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
508
Enrollment target
20
Study locations

NCT07391657 is a Phase 3 study of Relapsed Refractory Multiple Myeloma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 508 participants, above the 72-participant average among 4 other Relapsed Refractory Multiple Myeloma trials with a reported enrollment target (606% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07391657, a Phase 3 study of Relapsed Refractory Multiple Myeloma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
508 participants
Enrollment target
20
Study locations

Study Summary

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.

Conditions Studied

Relapsed Refractory Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Daratumumab
  • DRUG Carfilzomib
  • BIOLOGICAL AZD0120
  • DRUG Bortezomib

Study Locations (20)

Arizona

  • Research Site - Gilbert
  • Research Site - Phoenix
  • Research Site - Tucson

Massachusetts

  • Research Site - Boston
  • Research Site - Boston
  • Research Site - Boston

California

  • Research Site - La Jolla
  • Research Site - Santa Monica

Illinois

  • Research Site - Chicago
  • Research Site - Park Ridge

Colorado

  • Research Site - Denver

Connecticut

  • Research Site - New Haven

District of Columbia

  • Research Site - Washington D.C.

Georgia

  • Research Site - Atlanta

Trial Details

FieldValue
Enrollment Target 508 participants
Start Date 2026-02-23
Est. Completion 2030-07-29
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07391657

The ClinicalTrials.gov registry entry for NCT07391657 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 508 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 72-participant average among 4 other Relapsed Refractory Multiple Myeloma trials with a reported enrollment target (606% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Relapsed Refractory Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.

NCT07391657 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Arizona, Massachusetts, California.

Frequently Asked Questions

What is clinical trial NCT07391657 about?

NCT07391657 is a clinical study titled "A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)". This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexam...

What is the current status of trial NCT07391657?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 508 participants. The study started on 2026-02-23. Estimated completion is 2030-07-29.

What conditions does trial NCT07391657 study?

This clinical trial studies the following conditions: Relapsed Refractory Multiple Myeloma.

What interventions are being tested in trial NCT07391657?

The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Carfilzomib (DRUG), AZD0120 (BIOLOGICAL), Bortezomib (DRUG).

Who is sponsoring clinical trial NCT07391657?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07391657 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsed Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Relapsed Refractory Multiple Myeloma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.